Document is current
Any future updates will be listed below
-
Authors
Clark, Iain C. https://orcid.org/0000-0001-9082-0253
Fontanez, Kristina M. https://orcid.org/0000-0002-3318-0111
Meltzer, Robert H.
Xue, Yi
Hayford, Corey
May-Zhang, Aaron https://orcid.org/0000-0002-9017-0657
D’Amato, Chris
Osman, Ahmad
Zhang, Jesse Q.
Hettige, Pabodha
Ishibashi, Jacob S. A. https://orcid.org/0000-0003-2045-4387
Delley, Cyrille L.
Weisgerber, Daniel W.
Replogle, Joseph M. https://orcid.org/0000-0003-1832-919X
Jost, Marco
Phong, Kiet T.
Kennedy, Vanessa E.
Peretz, Cheryl A. C.
Kim, Esther A.
Song, Siyou
Karlon, William
Weissman, Jonathan S. https://orcid.org/0000-0003-2445-670X
Smith, Catherine C.
Gartner, Zev J.
Abate, Adam R. https://orcid.org/0000-0001-9614-4831
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (K22AI152644, DP2AI154435, F31NS115380, K99GM130964, 1RM1HG009490-01)
Howard Hughes Medical Institute
Damon Runyon Cancer Research Foundation (CI-99-18)
American Cancer Society (132032-RSG-18-063-01-TBG)
Leukemia and Lymphoma Society
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 20 January 2023
First Online: 6 March 2023
Competing interests
: A.R.A. filed a patent related to templated emulsification and is a founder of Fluent Biosciences. I.C.C. consults for Fluent Biosciences and is on its Scientific Advisory Board. K.M.F., R.H.M., Y.X., C.H., A.O., P.H., J.S.A.I., J.Q.Z., A.M.-Z. and C.D.A. are employees at Fluent Biosciences and are working to commercialize the PIP-seq technology. M.J. consults for Maze Therapeutics and Gate Biosciences. J.M.R. consults for Maze Therapeutics and Waypoint Bio. J.S.W. declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, DEM Biosciences, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics and Velia Therapeutics. All other authors have no competing interests to declare.
